"Around 99 per cent of the promised target was achieved by AIIMS. However, we have finished our enrollment after achieving the target in toto," he said.
Dr. C Prabhakar Reddy, principal investigator of Covaxin's phase III clinical trial at Nizam's Institute of Medical Sciences, Hyderabad, said that a few sites missed their individual target by a few numbers.
"However, the sites which over achieved their target compensated for it," he added.
While many sites struggled to find volunteers for the phase 3 study, a few sites registered them in abundance. AIIMS Patna, one of the clinical sites for Covaxin undertook around 1,400 subjects despite its individual target set at 1,000.
IANS had earlier reported that AIIMS Delhi and several other clinical sites were facing the dearth of volunteers since people were unwilling to participate in the exercise, hoping that they would receive the vaccine anyway once it is rolled-out by the government.
The phase III study of the Covaxin, which initially spanned at 25 clinical sites across the country, inducted several more sites in the last week of December since many sites were unable to find the volunteers for the study.
Dr. Dhananjay Lad, co-investigator of the trial at Redkar Hospital, Goa, told IANS that the trial was extended to around 30 clinical sites.
"A few sites were also removed in the process because of several reasons. One of the reasons was inability to enroll a bare minimum number of participants," he said.
The trial was started with three sites each in Uttar Pradesh (Aligarh Muslim University), West Bengal (ICMR-National Institute of Cholera and Enteric Diseases) and Tamil Nadu (Directorate of Public Health and Preventive Medicine) on November 10.
Covaxin has been given approval for restricted emergency use by India's drug regulator. While the efficacy of the vaccine is yet to be determined, it was given a go-ahead by the Drug Controller General of India (DCGI) citing public interest.
Covaxin is indigenously developed by the Bharat Biotech, in collaboration with the Indian Council of Medical Research (ICMR).
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.